Form 8-K - Current report:
SEC Accession No. 0001213900-25-019779
Filing Date
2025-03-04
Accepted
2025-03-04 08:57:41
Documents
15
Period of Report
2025-03-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0232881-8k_adial.htm   iXBRL 8-K 26875
2 PRESS RELEASE, ISSUED BY ADIAL PHARMACEUTICALS, INC. ON MARCH 4, 2025 ea023288101ex99-1_adial.htm EX-99.1 26217
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3998
  Complete submission text file 0001213900-25-019779.txt   239773

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE adil-20250304.xsd EX-101.SCH 3006
5 XBRL LABEL FILE adil-20250304_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE adil-20250304_pre.xml EX-101.PRE 22353
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0232881-8k_adial_htm.xml XML 3687
Mailing Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901
Business Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 434-422-9800
ADIAL PHARMACEUTICALS, INC. (Filer) CIK: 0001513525 (see all company filings)

EIN.: 800667150 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38323 | Film No.: 25701736
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)